The Society for Clinical Research Sites (SCRS) has launched the Global Impact Partnership (GIP) Program. In just over one month, 12 organizations have joined as partners to provide ongoing development, feedback and support of industry initiatives designed to include and improve the voice of clinical research sites. 

The GIP board will work in tandem with SCRS’ Leadership Council to identify the work streams most significant to the success of research sites across the world.  Each GIP member will appoint one executive level team member to represent its organization, and each organization has made a two year commitment to SCRS. 

The founding GIP industry partners include: Amgen, AstraZeneca, Eli Lilly, PPD and Roche.GIP professional partners include: Acurian, Aspire IRB, Bio-Optronics, CFS Clinical, Clinical Site Services, DAC Patient Recruitment Services and ePharmaSolutions.

The GIP board will work toward industry changes, from operational management to contracts, to subject retention and more. The collaboration with SCRS will continue throughout the year.

"The response our community of sites has received from industry has affirmed that the mission of SCRS to represent the global site community and ensure our voice is heard was long overdue, and they want to be a part of the advancement of SCRS,” said SCRS president Christine Pierre.